Sekhar Konjeti R, Spitz Douglas R, Harris Stephanie, Nguyen Trung T, Meredith Michael J, Holt Jeffrey T, Gius David, Marnett Lawrence J, Summar Marshall L, Freeman Michael L
Dept of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Free Radic Biol Med. 2002 Apr 1;32(7):650-62. doi: 10.1016/s0891-5849(02)00755-4.
Exposure of HepG2 cells to nonsteroidal anti-inflammatory drugs (i.e., indomethacin and ibuprofen; NSAIDs) as well as resveratrol, caused increased expression of the mRNAs coding for the catalytic (Gclc) and modifier (Gclm) subunits of the glutathione synthetic enzyme, gamma-glutamylcysteine synthetase. In addition, indomethacin exposure increased intracellular glutathione content as well as inhibited glutathione depletion and cytotoxicity caused by diethyl maleate. Indomethacin-induced increases in the expression of gamma-glutamylcysteine synthetase mRNA were preceded by increases in steady state levels of intracellular pro-oxidants and glutathione disulfide accumulation. Simultaneous incubation with the thiol antioxidant N-acetylcysteine (NAC) inhibited indomethacin-mediated increases in GCLC mRNA, suggesting that increases in GCLC message were triggered by changes in intracellular oxidation/reduction (redox) reactions. Indirect immunofluorescence using intact cells demonstrated that indomethacin induced the nuclear translocation of Nrf2, a transcription factor believed to regulate GCLC expression. Immunoprecipitation studies showed that indomethacin treatment also inhibited Nrf2 tethering to KIAA0132 (the human homolog of Keap1 accession #D50922), which is believed to be a negative regulator of Nrf2. Consistent with this idea, over-expression of Nrf2 increased GCLC reporter gene expression and over-expression of KIAA0132 inhibited GCLC reporter gene activity as well as inhibited indomethacin-induced increases in the expression of GCLC. Finally, simultaneous treatment with NAC inhibited both indomethacin-induced release of Nrf2 from KIAA0132 and indomethacin-induced nuclear translocation of Nrf2. These results demonstrate that NSAIDs and resveratrol cause increases in the expression of gamma-glutamylcysteine synthetase mRNA and identify these agents as being capable of stimulating glutathione metabolism. These results also support the hypothesis that indomethacin-induced transcriptional activation of GCLC involves the redox-dependent release of KIAA0132 from Nrf2 followed by the nuclear translocation of Nrf2.
将HepG2细胞暴露于非甾体抗炎药(即吲哚美辛和布洛芬;NSAIDs)以及白藜芦醇中,会导致编码谷胱甘肽合成酶γ-谷氨酰半胱氨酸合成酶催化亚基(Gclc)和调节亚基(Gclm)的mRNA表达增加。此外,吲哚美辛处理会增加细胞内谷胱甘肽含量,并抑制马来酸二乙酯引起的谷胱甘肽耗竭和细胞毒性。在吲哚美辛诱导γ-谷氨酰半胱氨酸合成酶mRNA表达增加之前,细胞内促氧化剂的稳态水平升高,谷胱甘肽二硫化物积累。与硫醇抗氧化剂N-乙酰半胱氨酸(NAC)同时孵育可抑制吲哚美辛介导的GCLC mRNA增加,这表明GCLC信息的增加是由细胞内氧化/还原(氧化还原)反应的变化触发的。使用完整细胞的间接免疫荧光显示,吲哚美辛诱导了Nrf2的核转位,Nrf2是一种据信调节GCLC表达的转录因子。免疫沉淀研究表明,吲哚美辛处理还抑制了Nrf2与KIAA0132(Keap1登录号#D50922的人类同源物)的结合,KIAA0132据信是Nrf2的负调节因子。与此观点一致,Nrf2的过表达增加了GCLC报告基因的表达,而KIAA0132的过表达抑制了GCLC报告基因的活性,并抑制了吲哚美辛诱导的GCLC表达增加。最后,与NAC同时处理可抑制吲哚美辛诱导的Nrf2从KIAA0132释放以及吲哚美辛诱导的Nrf2核转位。这些结果表明,NSAIDs和白藜芦醇会导致γ-谷氨酰半胱氨酸合成酶mRNA表达增加,并确定这些药物能够刺激谷胱甘肽代谢。这些结果还支持以下假设:吲哚美辛诱导的GCLC转录激活涉及KIAA0132从Nrf2的氧化还原依赖性释放,随后是Nrf2的核转位。